Shire plc and Rani Therapeutics have entered a collaboration to exclusively conduct research using the Rani Pill technology for the oral delivery of factor VIII (FVIII) therapy for hemophilia A. Shire has an exclusive option to negotiate a license to develop and commercialize the technology for delivery of FVIII therapy following feasibility studies. Shire has also made an equity investment in Rani Therapeutics .

Rani Therapeutics has developed a new approach for the oral delivery of large molecules, including peptides, proteins, and antibodies, using the Rani Pill, a Capsule that delivers an intestinal injection without exposing medication to digestive enzymes. Once the capsule is consumed, it stays protected until it enters the small intestine and delivers medication into the intestinal wall where delivery is expected to be pain free.

"Shire is proud to partner with Rani Therapeutics to pioneer the investigation of oral delivery of factor therapy for the hemophilia community," said Fritz Scheiflinger, head of Global Research, Shire. "With Shire's in-depth scientific expertise and leadership position in hemophilia and Rani Therapeutics' deep experience in engineering and material science, we are excited by the potential of this partnership to reduce the chronic burden of hemophilia on patients' everyday lives by researching an oral option to deliver FVIII to patients. We strive to provide hemophilia patients with innovative therapies that are effective and do not expose patients to additional risks."

"We are very pleased to collaborate with Shire on the development of oral FVIII delivery," said Mir Imran, chairman and chief executive officer, Rani Therapeutics. "With this technology, though early in development in hemophilia, we hope to improve Compliance , quality of life and outcomes for patients with hemophilia by offering a painless and more convenient oral delivery."